Quanterix Kicks Off West Coast Seminar Series In San Francisco

Following the Company’s successful participation in the Powering Precision Health Summit, Quanterix is bringing its insights and innovations to the West Coast

LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, today announced its inaugural “What Lies Beneath” West Coast seminar series, which will discuss its ultra-sensitive Simoa technology and how it is being used in a variety of clinical and translational research applications. The first seminar will be held in San Francisco at the Hilton Garden Inn today, November 3^rd from 9:00am to 4:00pm PDT.

“Probing the depths of the peripheral immune system: ultra sensitive quantification of cytokines for immuno-oncology and autoimmune disease research”

Quanterix executives, customers and industry thought leaders will join together to showcase Simoa’s ability to measure biomarkers at the earliest stages of disease progression and treatment monitoring in an effort to understand the biology of health and disease. Each seminar will provide stimulating presentations in several different therapeutic areas, including oncology, neurology and cardiology, and will offer helpful workshops led by some of Quanterix’ top scientists.

“We are passionate about transforming today’s sick care to tomorrow’s precision healthcare,” said Kevin Hrusovsky, CEO and Executive Chairman, Quanterix. “Following our participation at the inaugural Powering Precision Health Summit (PPH), we are motivated to continue the momentum with inspiring discussions, revolutionary innovations and groundbreaking research that stemmed from PPH. With these seminars, we will build additional awareness to the importance of precision health and further showcase the power of ‘science first’ through a series of important research initiatives using our Simoa technology.”

In addition to hearing opening remarks from Dr. Mark Roskey, vice president and general manager of applications and reagents at Quanterix, and receiving an in-depth workshop on the Simoa technology from Quanterix scientists, attendees will also hear from the following Quanterix customers:

• Genentech, Jeremie Decalf, will discuss: “Ultra-sensitive detection of interferon alpha protein by Simoa, new insights into disease pathogenesis”
• Myriad RBM, Dominic Eisinger, will discuss: “Probing the depths of the peripheral immune system: ultra sensitive quantification of cytokines for immuno-oncology and autoimmune disease research”
• Amgen, Monica Gavala, will discuss: “Evaluation of trace levels of Asthma-relevant Cytokines in serum using the high sensitivity Quanterix Simoa HD-1 platform”

Additional seminars will be held in Seattle on December 6^th at the Crowne Plaza and San Diego on December 7^th at the Embassy Suites. To learn more about the series and register to attend the Seattle seminar, please visit: http://go.quanterix.com/speaker-series-seattle, or to register for the San Diego seminar, please visit: http://go.quanterix.com/speaker-series-san-diego.

About Quanterix
Quanterix is a company that’s digitizing biomarker analysis to advance the science of precision health. The company’s digital health solution, Simoa, is changing the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. In doing so, Quanterix enables much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for applications in a majority of therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts.